Introduction
============

Ribulose-1,5-bisphosphate carboxylase/oxygenase (RubisCO, EC 4.1.1.39) is believed to be the most abundant enzyme on Earth ([@B15]; [@B29]). It is the key enzyme of the autotrophic Calvin-Benson-Bassham (CBB) cycle and catalyzes the carboxylation of ribulose-1,5-bisphosphate (RuBP) to 3-phosphoglycerate (3-PGA) ([@B3]). Since the CBB cycle is estimated to account for most of Earth's net primary production (\>99.5% of 105 × 10^9^ tons/year) ([@B16]; [@B30]), it is important to understand RubisCO expression and its activation in many different organisms.

The RubisCO enzyme is widespread and can be found in plants, algae, cyanobacteria, many autotrophic bacteria (phototrophs and chemolithotrophs), and archaea ([@B35]; [@B18]). Although four types of structural RubisCOs are known, only the RubisCO form I (CbbLS) and the form II (CbbM) are evidenced to operate in the classical CBB cycle ([@B3]). For the expression and activation of a catalytically active form I and form II RubisCO distinct transcriptional regulators and activases are essential ([@B22]; [@B11]; [@B37]). LysR-type transcriptional regulators (LTTRs) have been found adjacent to the structural RubisCO genes in several genomes and are evidenced to regulate their transcription ([@B11]). LTTRs can function as an activator and/or as a repressor for their target genes ([@B22] and references therein), but can also positively autoregulate their own transcription ([@B2]). Indeed, LTTR associated regulation can be highly complex as is indicated by LTTRs which need to interact with other transcriptional regulators ([@B19]; [@B10]). Since RubisCO forms inhibited complexes with its substrate RuBP but also with other sugar phosphates ([@B37]), the removal of the active site inhibitor is essential for proceeding with the RubisCO catalyzed carboxylation reaction. In case of plant green-type and α-proteobacterial red-type form I RubisCOs, this is done by the RubisCO activase (rca) and CbbX, respectively ([@B25]; [@B23]). CbbQ (AAA+ATPase) and CbbO (von Willebrand factor type A) represent a third class of RubisCO activases and were shown to act on green-type form I RubisCOs of chemoautotrophic bacteria ([@B37]).

Given that the majority of microorganisms are currently unculturable ([@B1]), we recently developed an activity-based screen, which enables us to seek RubisCO active clones from metagenomic fosmid libraries ([@B6]). One of these newly discovered RubisCO active metagenomic clones stems from a fosmid library constructed with DNA from the Nibelungen vent field (8°18′S on the Mid-Atlantic Ridge): It exhibited similarities to genes from the gammaproteobacterial *Thiomicrospira crunogena* XCL-2 (96%). Our metagenomic fragment encodes a 13 kb RubisCO gene cluster and flanking DNA regions of additional 22.2 kb. The 13 kb DNA fragment encodes two divergently directed reading frames: (i) *lysR1*, *lysR2*, *cbbM*, *cbbQ-m*, and *cbbO-m*, and (ii) *cbbL*, *cbbS*, *cbbQ-1*, and *cbbO*-*1*. To date, only one study has ever investigated regulatory mechanisms in metagenome derived RubisCO gene clusters ([@B6]). Here, total RubisCO activity was significantly influenced when *cbbL* and *cbbM* neighboring genes were knocked out ([@B6]), but it remained unclear which of the two RubisCOs was primarily affected by these mutations. While most of the studies on RubisCO regulation investigate the regulation of alphaproteobacterial RubisCOs ([@B24]; [@B12]; [@B38]; [@B14]; [@B19]; [@B10]), little work exists on the regulatory machinery behind gammaproteobacterial RubisCO transcription ([@B21]). The arrangement of alphaproteobacterial RubisCOs and their associated genes as well as the location of the RubisCO gene clusters on the genome are very different to what is observed on our metagenomic fragment. For example, while the alphaproteobacterial *Rhodobacter capsulatus* RubisCO form I gene cluster is arranged like our RubisCO form I gene cluster (*lysR1 cbbLSQO*), the RubisCO form II gene cluster is considerably different to that on our metagenomic fragment (*cbbFPTGAM* versus *cbbMQO*, respectively) ([@B24]) suggesting different interactions with respect to regulatory processes. Also, our metagenomic RubisCO form I and form II gene clusters are located within each other's vicinity on a 13 kb DNA fragment. In contrast, the RubisCO gene clusters of the so far investigated *Alphaproteobacteria* are either encoded on different chromosomes (*Rhodobacter sphaeroides*) or on distant regions of the genome (separated by 2 Mb or 1.4 Mb, *Rhodobacter capsulatus* and *Rhodopseudomonas palustris*, respectively) ([@B24]; [@B13]; [@B19]). The here investigated metagenome derived form I and form II RubisCOs, thus, represent a unique opportunity to investigate the role that genes and respective products have on the expression and activation of two forms of RubisCOs from an uncultured Gammaproteobacterium colonizing a chemically dynamic environment.

Materials and Methods {#s1}
=====================

Bacterial Strains, Vectors, and Constructs, Media, and Growth Conditions
------------------------------------------------------------------------

The bacterial strains, vectors, and constructs used in this study are summarized in **Table [1](#T1){ref-type="table"}**. *Escherichia coli* cultures were routinely grown on lysogeny broth (LB) medium ([@B5]). For cloning procedures cultures were incubated at 37°C. If cultivated for measuring recombinant RubisCO activities, the growth temperature was lowered to 28°C, while cultures grown as part of over expression experiments were incubated at 17°C or 22°C. If required, the following supplements were added: ampicillin, 100 μg ml^-1^; 5-bromo-4-chloro-3-indolyl-β-[D]{.smallcaps}-galactopyranoside (X-gal), 50 μg ml^-1^, chloramphenicol, 12.5 μg ml^-1^; isopropyl β-[D]{.smallcaps}-1-thiogalactopyranoside (IPTG), 100 μg ml^-1^ (cloning) or 0.1--1 mM (expression); kanamycin, 50 μg ml^-1^, and tetracycline, 10 μg ml^-1^.

###### 

Strains, vectors, and constructs used in this study.

  Strain, plasmid or construct   Genotype or characteristics                                                                                                                                                                  Size \[bp\]   Source
  ------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------- -------------------------------------------
  Epi300^TM^-T1^R^               F^-^, *mcr*A, Δ(*mrr*-*hsd*RMS-*mcr*BC) Φ80*dlac*ZΔM15, Δ*lac*X74, *rec*A1 *end*A1, *ara*D139, Δ(*ara, leu*)7697, *gal*U, *gal*K, λ^-^, *rps*L, *nup*G, *trf*A, *ton*A, *dhfr*               /             epicentre^®^ (Madison, WI, United States)
  *E. coli* Rosetta-gami 2       Δ(*ara*-*leu*)7697 Δ*lac*X74 Δ*pho*A *Pvu*II *pho*R, *ara*D139, *ahp*C, *gal*E, *gal*K, *rps*L (DE3), F′\[lac*^+^* lac*I^q^* pro\] *gor*522::Tn10 *trx*B *p*RARE2 (Cam^R^, Str^R^, Tet^R^)   /             Novagen/Merck (Darmstadt, Germany)
  pCC1FOS^TM^                    Fosmid cloning vector, oriV, ori2, *red*F, *rep*E, *par*A, *par*B, *par*C, *cos, lox*P, *lac*Z, Cam^R^, P T7                                                                                 8,139         epicentre^®^ (Madison, WI, United States)
  pet21a                         Expression vector, *lac*I, Amp^R^, P T7, C-terminal His 6-tag coding sequence                                                                                                                5,443         Novagen/Merck (Darmstadt, Germany)
  71C2                           pCC1FOS metagenomic fosmid vector containing a RubisCO gene cluster (*cbbO-mQ-mM lysR2 lysR1 cbbLSQ-1O-1*) and 22.2 kb flanking DNA                                                          35,195        [@B6]
  71C2II                         pCC1FOS vector containing a metagenome derived RubisCO gene cluster (*cbbO-mQ-mM lysR2 lysR1 cbbLSQ-1O-1*) subcloned from 71C2                                                               13,023        [@B6]
  22IIΔ*cbbM*                    Transposon clone based on 71C2II with an insertion in the *cbbM* structural gene at position 171aa of 459aa                                                                                  14,244        [@B6]
  24IIΔ*cbbL*                    Transposon clone based on 71C2II with an insertion in the *cbbL* structural gene at position 41aa of 472aa                                                                                   14,244        [@B6]
                                                                                                                                                                                                                                            
  pet21a::*cbbL*                 *cbbL* cloned from 71C2                                                                                                                                                                      1,421         This study
  pet21a::*cbbM*                 *cbbL* cloned from 71C2                                                                                                                                                                      1,386         This study
                                                                                                                                                                                                                                            
  pet21a::*lysR1*                *lysR1* cloned from 71C2                                                                                                                                                                     932           This study
  pet21a::*lysR2*                *lysR2* cloned from 71C2                                                                                                                                                                     950           This study

Characteristics of double transposon clones constructed in this study are indicated in Supplementary Table
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Construction of Double Transposon Mutant Libraries
--------------------------------------------------

Two double transposon mutant libraries were constructed from two versions of the 13 kb metagenomic fragment consisting of the RubisCO gene cluster (*cbbO-mQ-mM lysR2 lysR1 cbbLSQ-1O-1*; accession: KJ639815.1) using the EZ-Tn5^TM^ \<TET-1\> Tnp Transposome^TM^ Kit (epicentre^®^, Madison, WI, United States) according to manufacturer's instructions, with chemically competent Epi300^TM^ -- T1^R^ (epicentre^®^) as the host. One library was constructed with transposon clone 22II, where the *cbbM* structural gene was deleted (Δ*cbbM)*. The second library was constructed using transposon clone 24II, where the *cbbL* structural gene was impaired (Δ*cbbL*). Clones containing fosmids with \<TET-1\> insertions were selected on LB agar plates using the following antibiotic additions: (i) chloramphenicol (12.5 μg ml^-1^) for selecting the fosmid vector, (ii) kanamycin (50 μg ml^-1^) to verify the presence of the first insertion, i.e., Δ*cbbM* or Δ*cbbL*, and (iii) tetracycline (100 μg ml^-1^) to verify the insertion of the second transposon element. Fosmids of double transposon clones were isolated from autoinduced cultures (for detailed information on autoinduction procedure see the manual for the CopyControl^TM^ Fosmid Library Production Kit, epicentre^®^) using the High-Speed Plasmid Mini Kit (Geneaid, New Taipei City, Taiwan) according to manufacturer's instruction. Isolated fosmids were sequenced starting from the \<TET-1\> insertion using the TET-1 FP-1 forward and TET-1 RP-1 reverse primers (see manual of the EZ-Tn5^TM^ \<TET-1\> Insertion Kit, epicentre^®^) to identify the exact insertion position. Selected clones were tested for their RubisCO activities.

RubisCO Activity Assay
----------------------

For RubisCO activity measurements double transposon clones were cultivated at 28°C on 200 ml pre-heated LB medium supplemented with chloramphenicol (12.5 μg ml^-1^), kanamycin (50 μg ml^-1^), tetracycline (10 μg ml^-1^), and autoinduction solution \[1x final concentration (epicentre^®^)\] in 1 l flasks with shaking (130 rpm) and harvested after 18 h by centrifugation (9,800 × *g*, 10 min, and 4°C). Subsequently crude extracts were prepared. For this purpose, cell pellets were washed twice with buffer A \[100 mM Tris-HCl (pH 7.8), 10 mM MgCl~2~, 1 mM EDTA, 25 mM NaHCO~3~ and 1 mM DTT\] before resuspension in 2 ml of the same buffer. Cells were disrupted by the French pressure cell press method, followed by centrifugation (19,580 × *g*, 20 min, and 4°C), as described before ([@B6]). The generated crude extracts were finally used as template to perform the RubisCO activity assay, where the concentrations of the reactant (RuBP) and the product (3-PGA) of RubisCO reaction were quantified over time using High-Performance Liquid Chromatography (HPLC) ([@B6]). At least two biological replicates and three technical replicates were used for the RubisCO activity assay. Mean values of technical replicates were used to calculate the overall mean. Errors of RubisCO activity measurements were calculated with the Gaussian propagation of error. Standard derivations of technical replicates were propagated forward and are thus entered into the equation. Significant differences were calculated using an unpaired *t*-test with equal variance and two-tailed distribution. For each performed HPLC run different controls were tested additionally to the measured samples. The crude extract of the metagenome derived fosmid clone 71C2 containing the RubisCO gene cluster (*cbbO-mQ-mM lysR2 lysR1 cbbLSQ-1O-1*) and 22.2 kb flanking DNA serves as positive control and the crude extract of an *E. coli* fosmid clone without RubisCO genes encoded on its fosmid insert serves as a negative control. A protein free reference sample with 5 mM RuBP and 5 mM 3-PGA dissolved in buffer A were furthermore applied through the assay and used (i) for sample peak assignment and (ii) to gather the non-enzymatic degradation of educts and products. The latter was used to calculate the pseudo-activity which is subtracted from each sample activity.

Quantitative Reverse Transcriptase PCR
--------------------------------------

Clones were cultivated in 100 ml flasks on 20 ml LB media supplemented with autoinduction solution \[1x final concentration (epicentre^®^)\] and the following antibiotics: chloramphenicol (12.5 μg ml^-1^) for the fosmid subclone 71C2II, chloramphenicol (12.5 μg ml^-1^) and kanamycin (50 μg ml^-1^) for transposon clones 22II (Δ*cbbM*), 24II (Δ*cbbL*), 6II (Δ*lysR1*), and 149II (Δ*lysR2*), and chloramphenicol (12.5 μg ml^-1^), kanamycin (50 μg ml^-1^), and tetracycline (10 μg ml^-1^) for the double transposon clones 22II2B2 (Δ*cbbM* Δ*lysR1*), 22II3A3 (Δ*cbbM* Δ*lysR2*), 24II1H1 (Δ*cbbL* Δ*lysR1*), and 24II1H7 (Δ*cbbL* Δ*lysR2*). Cultures were allowed to grow until an optical density (λ = 600 nm) between 2.0 and 3.0 was reached \[for clone 6II (Δ*lysR1*) 24 h, all other clones 16 h\]. Total RNA was isolated with the UltraClean^®^ Microbial RNA Isolation Kit (MO BIO Laboratories, Inc., Carlsbad, CA, United States) according to manufacturer's instructions with the exception that only 1 ml cell culture was harvested instead of the recommended 2 ml. Subsequently, genomic DNA was removed by using the RTS DNase^TM^ Kit (MO BIO Laboratories, Inc.) following the provided protocol, but with the modification that after half an hour an additional microliter RTS DNase was added. The reaction was incubated at 37°C for further 30 min followed by RTS DNA removal using 10 μl instead of 5 μl RTS DNase removal resins. One thousand two hundred microgram isolated RNA was used to synthesize cDNA with Invitrogen's SuperScript^®^ VILO^TM^ cDNA Synthesis Kit (Life Technologies^TM^, Darmstadt, Germany), according to manufacturer's instructions. The generated cDNA was used to examine the fold change of RubisCO form I (*cbbL*) and form II (*cbbM*) structural genes during expression in above mentioned transposon and double transposon clones relative to the intact version 71C2II. The expression data were normalized to the transcripts of three different genes, namely (i) the chloramphenicol-acetyltransferase (*cat*) gene, which is encoded on the fosmid vector and reflects its copy number, (ii) the RNA polymerase sigma factor *rpoD*, which is a housekeeping gene, and (iii) the 16S rRNA encoding gene. For this purpose, cDNA was diluted 1--10 and the cDNA that was derived from transcripts was used as a template for the amplification of *cbbL* and *cbbM* genes as well as the three different housekeeping genes. The SYBR^®^ Select Master Mix, CFX (Applied Biosystems^®^ by Life Technologies^TM^) and the following primer pairs were used: for (i) *cbbL* -- cbbL_810F and cbbL_1115R, for (ii) *cbbM* -- cbbM_647F and cbbM_976R, for (iii) *cat* -- ChlR_821F and ChlR_1104R, for (iv) *rpoD* -- rpoD_416F and rpoD_720R, and for (v) the 16S rRNA gene -- 16S_280F and 16S_564R (for details on primer characteristics see **Table [2](#T2){ref-type="table"}**). The qRT-PCR on the MJ Mini^TM^ Gradient Thermal Cycler (Bio-Rad, Hercules, CA, United States) was performed under the following conditions: 95°C for 2 min followed by 40 cycles of 98°C for 15 s, 51°C for 20 s, and 72°C for 30 s. Each run contains, next to the samples, various controls like (i) the non-template controls, (ii) the no reverse transcriptase control as well as (iii) an inter run calibrator to ensure comparability between different runs, i.e., one reaction from the previous plate was repeated on the new plate. At least two biological and three technical replicates were measured and used to calculate fold changes (2^-ΔΔCt^). Technical replicates were arithmetically averaged and resulting mean values were used to calculate an overall mean. Errors were calculated with the Gaussian propagation of error. Standard derivations of technical replicates were entered into the equation and thus propagated forward. Significant differences were calculated from log transformed values using an unpaired *t*-test with equal variance and two-tailed distribution.

###### 

Primers used in this study.

  Primer description                             Sequence 5′-3′                    T~annaeling~ \[°C\]   Product length \[bp\]
  ---------------------------------------------- --------------------------------- --------------------- -----------------------
  **Quantitative reverse transcriptase PCR**                                                             
  cbbL_810F 5′                                   AGGTCTTGCGAACTACTGTC              51                    306
  cbbL_1115R                                     CCAGAAGCAACTGGCATAAC                                    
  cbbM_647F                                      TCTGCACGGTAGCACATTTC              51                    330
  cbbM_976R                                      ATTTGACGGTCCTGCTGTTG                                    
  ChlR_821F                                      TAAGCATTCTGCCGACATGG              51                    284
  ChlR_1104R                                     CGATTTCCGGCAGTTTCTAC                                    
  rpoD_416F                                      GATCAACGACATGGGCATTC              51                    305
  rpoD_720R                                      CGTACTGTTCCAGCAGATAG                                    
  16S_280F                                       GGTCGCTTCTCTTTGTATGC              51                    285
  16S_564R                                       CCTTACCTGGTCTTGACATC                                    
  cbbO-m_700F                                    ACCTCATCGCCATAATGCTC              51                    223
  cbbO-m_922R                                    TTGCCGTCATGTTACTGGTC                                    
  cbbQ-m_2828F                                   GTGGCGGCATACACCATTAG              51                    147
  cbbQ-m_2974R                                   AGTCGAAGCGCACATCTTAC                                    
  cbbQ-1_9714F                                   GGTAGGTCGCTTCCTAATCG              51                    199
  cbbQ-1_9912R                                   GTGCGCTTCTACCAACTCAC                                    
  cbbO-1_12263F                                  CGCATGCCATCAATGGTATC              51                    263
  cbbO-1_12525R                                  GTCAATATCCGCTGGTTCAC                                    
  **Protein expression**                                                                                 
  CbbLF_NheI                                     GCTAGCACCATGGCTAAGACTTATAAC       50^1^/60^2^           1421
  CbbLR_BamHI                                    GGATCCGCCTTATGCTTAACATCTAGCTTAT                         
  CbbMF_NheI                                     GCTAGCATGGATCAGTCGAATCGTTATG      56^1^/62^2^           1386
  CbbMR_BamHI                                    GGATCCGCTTTGTGTACGCCCAACTTCTC                           
  LysR1F_NheI                                    GCTAGCATGCλCTTACATATAACCGCCCAGC   62^1^/67^2^           932
  LysR1R_BamHI                                   GGATCCGAGCGCGTGTCCGACATGG                               
  LysR2F_NheI                                    GCTAGCATGCCTGλAATTTCCATCC         51^1^/61^2^           950
  LysR2R_BamHI                                   GGATCCGAGCGAAATTGGTTAAACG                               
  **Preparation of Cy3-labeled DNA fragments**                                                           
  ncrQm-M_3427F                                  AGCCGCTTCATAAAGTTC                56.3                  371
  ncrQm-M_3797R                                  CAGATGCAGACACAATCTAC                                    
  ncrM-R2_4993F                                  TGCAGCAACTTCTAAGTAACC             62.2                  369
  ncrM-R2_5361R                                  ACAGGCGTTTAACCAATTTCG                                   
  ncrR2 L_7191F                                  CTGGGCGGTTATATGTAAG               57.7                  275
  ncrR2-L_7465R                                  TACACCGGCGTTATAAGTC                                     
  ncrS-Q1_9151F                                  AACCACGTTCGTTTGATTG               57.5                  331
  ncrS-Q1_9531R                                  TGGCTCGTCTTTAATAAGG                                     
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Polar Effects
-------------

Polar effects were investigated to determine whether transposon insertions have an impact on transcript abundances of genes located downstream of an insertion site. Therefore, transcript abundances of genes located downstream of *cbbM* and *cbbL* were measured for Δ*cbbM* (22II) and for Δ*cbbL* (24II), and compared with the transcript abundances in the intact version 71C2II. Investigated genes were (i) *cbbO-m* and (ii) *cbbQ-m* in Δ*cbbM* and (iii) *cbbQ-1* and (iv) *cbbO-1* in Δ*cbbL*. The cDNA used as template was the same as that isolated before for qRT-PCR of *cbbL* and *cbbM*. The qRT-PCR conditions were the same as mentioned above for the amplification of *cbbL* and *cbbM*, but with different primers: (i) *cbbO-m* -- cbbO-m_700F and cbbO-m_922R, for (ii) *cbbQ-m* -- cbbQ-m_2828F and cbbQ-m_2974R, for (iii) *cbbQ-1* -- cbbQ-1_9714F and cbbQ-1_9912R, and for (iv) *cbbO-1 --* cbbO-1_11263F and cbbO-1_12525R (for details on primer characteristics see **Table [2](#T2){ref-type="table"}**). Three biological and three technical replicates were measured and used to calculate fold changes (2^-ΔΔCt^). Statistics were calculated in the same way as has been described for qRT-PCR data of *cbbL* and *cbbM.*

Overexpression and Protein Purification
---------------------------------------

The four genes encoding CbbL, CbbM, LysR1, and LysR2 were cloned in the expression vector pet21a (Novagen/Merck, Darmstadt, Germany). The coding regions of the targeted genes were amplified from the fosmid DNA of the metagenome derived clone 71C2, whereby restriction sites for NheI and BamHI were inserted using following primer pairs: (i) for *cbbL* -- CbbLF_NheI and CbbLR_BamHI, (ii) for *cbbM* -- cbbMF_NheI and cbbMR_BamH1, (iii) for *lysR1* -- LysR1F_NheI and LysR1R_BamHI, and (iv) for *lysR2* -- LysR2F_NheI 5′- and LysR2R_BamHI (primer sequences, annealing temperatures and product length are listed in **Table [2](#T2){ref-type="table"}**). Amplification was done with the Pfu DNA Polymerase (Thermo Fisher Scientific, Waltham, MA, United States), following manufacturer's instructions. The amplified fragments were ligated in the pet21a expression vector (Novagen/Merck) using the previously inserted restriction sites (NheI and BamHI). This vector has a His-tag coding sequence for the C-terminus of the cloned protein. The constructed plasmids (i) pet21a::*cbbL*, (ii) pet21a::*cbbM*, (iii) pet21a::*lysR1*, and (iv) pet21a::*lysR2* were transformed into *E. coli* Rosetta-gami2 host strains. Verified clones were cultured at 17°C (CbbM) or at 22°C (CbbL, LysR1, and LysR2) in 200 ml LB supplemented with ampicillin (100 μg ml^-1^), tetracycline (10 μg ml^-1^), and chloramphenicol (12.5 μg ml^-1^) to an optical density (λ = 600 nm) of 0.7--0.8. IPTG was added to a final concentration of 0.1 mM for CbbL, 1 mM for CbbM, 1 mM for LysR1, and 0.1 mM for LysR2. The cultures were then grown over night at 17°C (CbbM) or at 22°C (CbbL, LysR1, and LysR2). Cells were harvested by centrifugation (7,600 × *g*, 8 min, and 8°C) and washed twice with 1x PBS buffer (137 mM NaCl, 2.7 mM KCl, 10 mM Na~2~HPO~4~, and 2 mM KH~2~PO~4~, pH = 7.4). Cell pellets were stored at -20°C until proceeding with His-tag purification using Ni-NTA agarose (Qiagen, Hilden, Germany) as described in protocol 14 of TheQia*expressionist* ([@B28]), with some modifications: Initially cell pellets were resuspended in 2 ml lysis buffer (containing 10 mM imidazole). Each lysate was passed through the French press in order to disrupt cells. Cellular debris were removed by centrifugation (19,580 × *g*, 20 min, and 4°C) and supernatant volumes were brought to 20 ml with lysis buffer. Afterward 2 ml Ni-NTA agarose was added to the diluted lysates, which were incubated for 2 h on ice (shaking). After pelleting (1,000 × *g*, 30 s, and 8°C) Ni-NTA resins were washed twice with washing buffer (containing 20 mM imidazole). The protein was eluted from the column with five volumes of elution buffer (containing 250 mM imidazole). The concentration of the total purified protein was measured by performing the Bradford assay as described previously ([@B8]) using bovine serum albumin as a standard. The proteins were further analyzed by SDS polyacrylamide gel electrophoresis using 12% (w/v) gels and Western-immunoblotting using 6-His-specific antibodies (see Supplementary Figure [1](#SM1){ref-type="supplementary-material"}).

Preparation of Cy3-Labeled DNA Fragments
----------------------------------------

In preparation for the mobility shift assay four non-coding regions located within the metagenome derived RubisCO gene cluster were Cy3-labeled, namely the non-coding regions between: (i) *cbbQ-m* and *cbbM*, (ii) *cbbM* and *lysR2*, (iii) *lysR1* and *cbbL* as well as (iv) *cbbS* and *cbbQ-1*. Labeling was done during amplification using Cy3-labeled dCTP's (1 mM, GE Healthcare, Little Chalfont, United Kingdom), a mixture of dATP, dTTP, and dGTP (2 mM), the Phusion DNA Polymerase (Thermo Fisher Scientific) and the following primer pairs: (i) ncrQm-M_3427F and ncrQm-M_3797R for the non-coding region between *cbbQ-m* and *cbbM*, (ii) ncrM-R2_4993F and ncrM-R2_5361R for the non-coding region between *cbbM* and *lysR2*, (iii) ncrR1-L_7191F and ncrR1-L_7465R for the non-coding region between *lysR1* and *cbbL*, and (iv) ncrS-Q1_9151F and ncrS-Q1_9531R for the non-coding region between *cbbS* and *cbbQ-1* (see **Table [2](#T2){ref-type="table"}** for primer sequences). PCR conditions were: Denaturation at 98°C for 10 s, primer annealing for 30 s at appropriated annealing temperatures (see **Table [2](#T2){ref-type="table"}**), and elongation at 72°C for 12 s (32 cycles).

Electrophoretic Mobility Shift Assay (EMSA)
-------------------------------------------

The mobility shift assay was based on a previously published protocol ([@B9]) but with modifications: Purified His~6~-CbbL, His~6~-CbbM, His~6~-LysR1, and His~6~-LysR2 were investigated for the ability to bind at the four non-coding regions amplified from the metagenome derived RubisCO gene cluster. For this purpose, proteins were tested (i) individually but also (ii) pairwise in combination with each other. The protein concentrations used for approaches with individual proteins ranged from 0 to 1,000 ng per 30 μl reaction mixture. For approaches with two different proteins up to 2,000 ng total protein per 30 μl were used in one reaction, which corresponds to a maximum of 1,000 ng of each protein and thus ensures the comparability with the single protein approaches. Regardless of whether one or two proteins were used for the assay, protein(s) was/were firstly incubated with a total of 200 ng salmon sperm DNA for 5 min at room temperature in binding buffer (50 mM Tris-HCl, 250 mM KCl, pH = 8.5) to prevent unspecific DNA shifts. After this Cy3-labeled DNA fragments were added (200 ng per 30 μl reaction) and reaction mixture was incubated at room temperature in the dark for further 20 min. Subsequently 5 μl loading dye (20% TBE buffer and 80% glycerol) was added and samples were loaded on a 5% TBE-polyacrylamide gel. Following electrophoresis at 50 mV for 3 h in cooled TBE-buffer, gels were visualized on a VersaDoc^TM^ MP4000 (Bio-Rad) at 550 nm and an exposure time of 300 ms.

Computational Analyses
----------------------

Distinct regulatory features were predicted for the DNA of the metagenome derived RubisCO gene cluster using different online tools. Promoter regions were predicted for all non-coding regions with the SoftBerry program BProm ([@B34]). We also searched for inverted repeats, which are putatively able to fold into stem-loop structures using Emboss Palindrome ([@B31]), with a minimum length for repeats of 8 nt and a maximum gap between repeated elements of 100 nt. With respect to the formation of stem-loop structures, inverted repeats with loops less than three bases were not taken into account, because they are thought to be sterically impossible and thus are believed not to be formed ([@B7]). LysR binding sites were identified manually by searching for the typical LysR binding motif TnA-n7/8-AnT which has been identified in other RubisCO harboring organisms before ([@B38]; [@B22] and references therein).

Results
=======

To understand the processes involved in expression of a fully active RubisCO form I (CbbLS) and form II (CbbM) enzyme, we constructed two double mutant libraries using a 13 kb metagenomic fragment encoding the RubisCO gene cluster. In one case, the Δ*cbbM* fragment of transposon clone 22II, and in the other case, the Δ*cbbL* fragment of transposon clone 24II provided the base for the second mutant library. These double mutants were used to study how gene deletions influence *cbbL* and *cbbM* transcription and respective enzyme activities. We also searched through the metagenomic DNA sequence *in silico* for putative LysR binding sites, promoter regions or structures capable of forming stem-loops -- possibly affecting transcription -- and determined experimentally whether RubisCO and LysR proteins and protein combinations bind to non-coding regions in the metagenomic fragment.

*cbbL* and *cbbM* Transcription after Gene Deletions
----------------------------------------------------

*cbbL* and *cbbM* transcription abundances were tested for eight mutants and normalized to three different reference genes (*cat*, *rpoD*, and 16S rRNA) (**Figure [1](#F1){ref-type="fig"}**). Generally, transcript levels of *cbbL* in Δ*cbbM* and of *cbbM* in Δ*cbbL* remained unchanged relative to the undeleted metagenomic fragment (71C2II). *cbbL* gene transcription was only significantly downregulated in Δ*lysR1* if *cbbM* was expressed, since no changes in *cbbL* transcript levels were observed in Δ*lysR1* Δ*cbbM*. In contrast, *cbbM* gene transcription was significantly upregulated in Δ*cbbL* Δ*lysR1* double transposon clone 24II1H1 (3-fold) and in Δ*cbbL* Δ*lysR2* double transposon clone 24II1H7 (15-fold).

![Fold change of *cbbL* and *cbbM* transcription. Fold change (2^-^ ^Δ^ ^ΔCt^) of *cbbL* (light-gray) and *cbbM* (dark-gray) transcripts expressed from selected transposon and double transposon clones normalized to the *cat* (chloramphenicol acetyltransferase), *rpoD*, and 16S rRNA genes. All data is relative to the 13 kb metagenomic fragment (clone 71C2II) encoding the RubisCO gene cluster (*cbbO-mQ-mM lysR*2 *lysR*1 *cbbLSQ1O1*). Bars and error bars indicate mean values and +/-- standard error. Black dots denote significantly different values (*p*-value ≤ 0.05).](fmicb-08-01303-g001){#F1}

*cbbL* and *cbbM* Activity after Gene Deletions
-----------------------------------------------

All RubisCO activities of clones from the double mutant libraries where either Δ*cbbM* (22II) or Δ*cbbL* (24II) was used for the construction of the double mutants can be viewed in **Figures [2A,B](#F2){ref-type="fig"}**, respectively. Total RubisCO activity of the undeleted 13 kb fragment (71C2II) increased considerably in Δ*cbbM* (22II) (5-fold). Additional deletions in *lysR1*, *lysR2*, *cbbQ-m*, and *cbbO-m* resulted in a significant decrease of RubisCO activity.

![Specific RubisCO activities and insertion positions of tested double transposon clones. Specific RubisCO activities and schematic gene arrangement of **(A)** double transposon clones constructed on the basis of the Δ*cbbM* transposon clone 22II and **(B)** double transposon clones constructed on the basis of the Δ*cbbL* transposon clone 24II. Identified open reading frames (ORFs) are indicated as arrows in the direction of transcription. Insertion sites are denoted by vertical black arrows and transposon clone numbers. Genes are color coded according to the bars indicating corresponding RubisCO activity. Gene abbreviations are as follows: *cbbO-m* -- von Willebrand factor type A; *cbbQ-m* -- ATPase AAA-type; *cbbM* -- ribulose-1,5-bisphosphate carboxylase/oxygenase large subunit, form II; *lysR2* -- transcriptional regulator, LysR family; *lysR1* -- transcriptional regulator, LysR family; *cbbL* -- ribulose-1,5-bisphosphate carboxylase/oxygenase large subunit, form I; *cbbS* -- ribulose-1,5-bisphosphate carboxylase small subunit; *cbbQ-1* -- ATPase, AAA-type; *cbbO-1* -- von Willebrand factor. Bars and error bars indicate mean values and +/-- standard error. The level of significant differences is denoted by dots where green is ≤0.05, yellow is ≤0.01, and red is ≤0.001.](fmicb-08-01303-g002){#F2}

Total RubisCO activity of the undeleted 13 kb fragment (71C2II) was significantly reduced in Δ*cbbL* (24II). When additionally deleting *lysR2* (24II1H7), the RubisCO activity increased (3.5-fold), restoring the original activity of clone 71C2II. In four of the tested double mutant Δ*cbbL* clones the RubisCO activity was considerably reduced. These were clone 24II1G2, where parts of the intergenic region of *cbbM* and *lysR2* were deleted, clone 24II2G1, where parts of the non-coding region between *cbbS* and *cbbQ-1* were deleted, and the two Δ*cbbL* Δ*cbbQ-1* clones (24II6H6 and 24II5G11). As expected, no RubisCO activity was measured for Δ*cbbL* Δ*cbbM.*

Putative Promoters, LysR Binding Sites and Stem-Loop Forming Structures
-----------------------------------------------------------------------

We searched the intergenic regions of our metagenomic fragment for structures which encode putative promoter regions that provide potential LysR binding sites or that may form stem-loops (**Figure [3](#F3){ref-type="fig"}**). We found 6 putative promoter binding sites, 15 putative LysR binding sites, and 18 putative stem-loop forming structures (for exact positions on the metagenomic fragment see Supplementary Figure [2](#SM1){ref-type="supplementary-material"}).

![Regulatory features predicted for the DNA of the metagenome derived RubisCO gene cluster. ORFs are displayed as gray arrows in the direction of transcription. The same gene abbreviations as specified in **Figure [2](#F2){ref-type="fig"}** are used. Predicted promoters are indicated by black arrows, inverted repeats (IR) are denoted by green arrows and putative LysR binding sites (bs) are represented by red boxes.](fmicb-08-01303-g003){#F3}

We also performed mobility shift assays to test whether LysR1, LysR2, CbbL, and CbbM or a combination of these proteins bind to the non-coding regions *cbbQ-m* and *cbbM*, *cbbM* and *lysR2*, *lysR1* and *cbbL* or *cbbS* and *cbbQ-1* (**Figure [4](#F4){ref-type="fig"}**). LysR1 binds to all tested non-coding regions (**Figure [4A](#F4){ref-type="fig"}**). Its binding ability is enhanced for the intergenic region *lysR1* and *cbbL* if CbbL or LysR2 are additionally present (**Figure [4B](#F4){ref-type="fig"}**). LysR2 alone appears to only bind to two non-coding regions: between *cbbQ-m* and *cbbM* and between *cbbM* and *lysR2* (**Figure [4A](#F4){ref-type="fig"}**). CbbM addition intensifies the binding ability to the *cbbM* and *lysR2* intergenic region (**Figure [4B](#F4){ref-type="fig"}**). The presence of CbbM also enables LysR2 to bind to two further non-coding regions, namely *lysR1* and *cbbL* as well as *cbbS* and *cbbQ-1* (**Figure [4B](#F4){ref-type="fig"}**). Other protein combinations likely reflect binding of one of the proteins alone.

![Binding of CbbL, CbbM, LysR1, and LysR2 to four different non-coding regions of the metagenome derived RubisCO gene cluster. Mobility shift assays with CbbL, CbbM, LysR1, and LysR2 individually **(A)** as well as in **(B)** combination are shown. Corresponding semi-quantitative data is depicted below each gel where the *y*-axis denotes intensity in percent relative to the unshifted band in lane 1. DNA fragments contained the non-coding regions between *cbbQ-m* and *cbbM*, *cbbM* and *lysR2*, *lysR1* and *cbbL*, and *cbbS* and *cbbQ-1*. The protein concentrations used for approaches with individual proteins, given per 30 μl reaction mixture: 0 ng (1), 10 ng (2), 25 ng (3), 50 ng (4), 100 ng (5), 250 ng (6), 500 ng (7), and 1000 ng (8). For approaches with two different proteins tested in one reaction the following protein concentrations per 30 μl reaction mixture were used: 0 ng (1), 25 ng (2), 50 ng (3), 100 ng (4), 250 ng (5), 500 ng (6), 1000 ng (7) and 2000 ng (8). Gene abbreviations are the same as described in **Figure [2](#F2){ref-type="fig"}**. Other abbreviation: ncr, non-coding region.](fmicb-08-01303-g004){#F4}

Discussion
==========

Possible CbbL Expression and Regulation
---------------------------------------

In the intergenic region of *lysR1* and *cbbL* two promoters were predicted: (i) one could be for *cbbL* transcription (with the -10 box 'AGGAATCAT' at position 7,271 bp and the -35 box 'TTGATA' at position 7,250 bp) and (ii) the other for *lysR1/lysR2* transcription with the -10 box at position 7,275 bp 'ATCATATAC' and with the -35 box at position 7,302 bp 'TAACAA' (Supplementary Figure [2](#SM1){ref-type="supplementary-material"}). This is in line with previous predicted functions for the non-coding region between *lysR* and *cbbL* in other organisms, where promoters for both directions were identified ([@B21]; [@B40]). Additionally, three and two putative LTTR binding sites upstream of the putative *cbbL* and *lysR1/lysR2* promoters, respectively, were recognized (**Figure [3](#F3){ref-type="fig"}**). These sites may be involved in LysR1 and/or LysR2 regulated *cbbL* transcription as well as autoregulation of their own transcription, as has been commonly demonstrated for enzymes of the LysR family ([@B33]; [@B22]). The mobility shift assay verified that binding sites are located in this non-coding region (**Figure [4](#F4){ref-type="fig"}**). Here, DNA binding of LysR1 is intensified by the presence of LysR2 or CbbL (**Figure [4B](#F4){ref-type="fig"}**). LysR2 is also capable of binding to this region, but only when CbbM proteins are available. Promiscuous heterotypic interactions between different LTTRs in *E. coli* have been shown before, but the relevance of such cross-interactions remains unknown ([@B20]). However, since our experiment showed that LysR1's DNA binding ability is increased by LysR2, one may conclude that LysR1 and LysR2 are also able to cross-interact and form heteromultimers with its non-cognate partner. The heteromultimer (LysR1+LysR2) may cause different regulatory effects relative to the homomultimers (LysR1+LysR1 or LysR2+LysR2). The role that CbbL and CbbM play for intensified LysR binding currently remains unclear but may be related to DNA or RNA stability. Mobility shift assays with RNA and the large RubisCO subunit of *Chlamydomonas reinhardtii* demonstrated CbbL's ability to bind to RNA in a sequence-independent manner under certain conditions ([@B42]).

Although *cbbL* transcription levels remained unchanged in Δ*cbbM* Δ*lysR1* and Δ*cbbM* Δ*lysR2* (**Figure [1](#F1){ref-type="fig"}**), these clones exhibited reduced CbbL activity (**Figure [2A](#F2){ref-type="fig"}**). This discrepancy may be explained if LysR proteins also act on the transcription of genes encoding proteins, which influence CbbL activity. Likely candidates encoded on this metagenomic fragment are CbbO-m, CbbQ-m, CbbQ-1, and CbbO-1, previously shown to be involved in post-translational activation of RubisCO enzymes ([@B37]). Indeed LysR1 proteins are demonstrated to bind upstream of *cbbQ-m/cbbO-m* and *cbbQ-1/cbbO-1* regions (**Figure [4A](#F4){ref-type="fig"}**). LysR2 can also bind upstream of *cbbQ-m/cbbO-m* and if CbbM is present can bind upstream of *cbbQ-1/cbbO-1*, too (**Figures [4A,B](#F4){ref-type="fig"}**, respectively). While the deletion of *cbbQ-m* and *cbbO-m* in Δ*cbbM* illustrated a RubisCO activity loss, CbbQ-1 and CbbO-1 did not have an effect on CbbL activity (**Figure [2A](#F2){ref-type="fig"}**). Based on the available information, we posit that CbbQ-m/CbbO-m activates CbbL and that LysR1 and LysR2 proteins promote CbbQ-m/CbbO-m expression (compare model in **Figure [5](#F5){ref-type="fig"}**).

![Model of gene regulation and possible protein interaction. Relevant transcriptional and post-translational regulatory processes hypothesized for the 13 kb comprising metagenome derived RubisCO gene cluster. Identified genes are indicated as arrows in the direction of transcription and marked in the same color as the corresponding mRNA and resulting gene products. Abbreviations used are the same as described in **Figure [2](#F2){ref-type="fig"}**.](fmicb-08-01303-g005){#F5}

Intriguingly, CbbM also appears to play a role for *cbbL* expression, which has not been observed in any other study before. The deletion of *cbbM* leads to a 5-fold RubisCO activity increase (**Figure [2A](#F2){ref-type="fig"}**) indicative of CbbM's repressive nature for *cbbL* expression. However, in Δ*cbbM cbbL* transcript levels are not elevated (**Figure [1](#F1){ref-type="fig"}**). Possible scenarios include that CbbM scavenges post-translational activators (CbbQ-m/CbbO-m), which are then not available for CbbL activation or that CbbM is involved in repressing CbbQ-m/CbbO-m, which may be needed for CbbL activation (**Figure [5](#F5){ref-type="fig"}**). For information on putative polar effects for *cbbQ-m*/*cbbO-m* transcript abundance caused by transposon insertion in the upstream neighboring *cbbM* gene see Supplementary Results and Discussion and Supplementary Figure [3](#SM1){ref-type="supplementary-material"}.

Possible CbbM Expression and Regulation
---------------------------------------

A putative promoter was identified upstream of *cbbM* (**Figure [3](#F3){ref-type="fig"}**), confirming recent results indicative of *cbbM* being transcribed alone in this fragment ([@B6]). In the intergenic region of *cbbM* and *lysR2* three putative LysR binding sites were predicted, two of which partially overlap ('LysR bs1*~cbbM~*,' 'LysR bs2/3*~cbbM~*,' see Supplementary Figure [2](#SM1){ref-type="supplementary-material"}). In *Xanthobacter flavus* the same arrangement of a single LysR binding site followed by two overlapping binding sites, between a RubisCO structural gene and a LysR transcriptional regulator was also identified and all three sites were evidenced to be functional ([@B38]). In our fragment LysR binding sites upstream of *cbbM* exist, which allow binding of LysR1 and LysR2 proteins (**Figure [4A](#F4){ref-type="fig"}**). LysR2 binding was even intensified if CbbM was present (compare **Figure [4B](#F4){ref-type="fig"}**). Upregulation of the *cbbM* transcript (**Figure [1](#F1){ref-type="fig"}**) and increasing RubisCO activity in the double mutant Δ*cbbL* Δ*lysR2* (**Figure [2B](#F2){ref-type="fig"}**) strongly suggest that LysR2 acts as a repressor for *cbbM* gene expression where CbbM itself contributes to intensified LysR binding ability and thus its own transcriptional regulation (**Figure [5](#F5){ref-type="fig"}**). The combination of CbbL and LysR1 also appears to result in a repressive *cbbM* transcriptional regulation but single mutations in *cbbL* and *lysR1* did not cause upregulation of the *cbbM* gene (see **Figure [1](#F1){ref-type="fig"}**). However, despite higher *cbbM* transcript levels in Δ*cbbL* Δ*lysR1*, this clone did not demonstrate an increase in RubisCO activity (**Figure [2B](#F2){ref-type="fig"}**), contrasting the transcriptional data at first glance. These results can be explained though if LysR1 also controls the expression of post-translational activators, which here only seems applicable if CbbL is also present. And indeed LysR1 appears to be able to bind upstream of *cbbQ-m*/*cbbQ-m* and of *cbbQ-1*/*cbbO-1* (**Figure [4](#F4){ref-type="fig"}**), where also putative LysR binding sites were recognized (**Figure [3](#F3){ref-type="fig"}**). Of these likely post-translational activators only the deletion of *cbbQ-1* caused a CbbM activity loss and thus makes its LysR regulated role in CbbM activation under the provided conditions highly likely. We thus suggest that CbbQ-1 activates CbbM and that LysR1 proteins may prevent CbbQ-1 expression if CbbL is present. Additionally, an insertion at position 9,463 bp, i.e., 15 bp upstream of the *cbbQ-1* transcription start in the Δ*cbbL* clone 24II, resulted in significantly reduced CbbM activity (see **Figure [2B](#F2){ref-type="fig"}**, clone 24II2G1). Even though this insertion is located downstream of putative regulatory features, the 1,674 bp comprising \<TET\> insertion represents a barrier the RNA polymerase most likely cannot simply overcome, which would result in an impaired *cbbQ-1* transcription and thus no CbbQ-1 would be present. Unexpectedly, the deletion in *cbbO-1*, downstream of *cbbQ-1*, did not alter RubisCO activity (**Figure [2B](#F2){ref-type="fig"}**). However, the elevated number of inverted repeats (5/18 identified on the metagenomic fragment) in the *cbbO-1* gene, which are theoretically capable of forming stem-loop structures, may indicate some fine-tuned transcriptional regulation ([@B36] and references therein). Under the provided conditions *cbbO-1* may be downregulated and under other environmental conditions may well be important for RubisCO activation.

In the intergenic region of *cbbM* and *lysR2* a large inverted repeat flanking 86 nt (IR8, see Supplementary Figure [2](#SM1){ref-type="supplementary-material"}) also exists. Such inverted repeats often form stem-loop structures that are important for controlling transcription initiation and termination, mRNA stabilization or genome plasticity ([@B36] and references therein). They also play roles in supporting DNA binding proteins in finding their binding sites ([@B17]). The IR8 in our metagenomic fragment may well represent such a signaling stem-loop structure that guides LysR to the LysR binding sites. An insertion of a tetracycline cassette in the left arm of the IR8 (clone 24II1G2), directly between the LysR binding sites 'bs1*~cbbM~*' and 'bs2/3*~cbbM~*' (see position 5,232 nt in Supplementary Figure [2](#SM1){ref-type="supplementary-material"}) resulted in a significant RubisCO activity loss (**Figure [2B](#F2){ref-type="fig"}**). One explanation could be that this structure is necessary for the expression of a functional CbbM. Since this insertion also separates the putative -10 from the -35 promoter box, the RubisCO activity loss may be due to the impaired promoter region.

Benefits and Drawbacks of Working with a Metagenomic Fragment in a Non-native System
------------------------------------------------------------------------------------

Restricting the work to culture-depended approaches, neglects the large majority of RubisCO gene clusters from uncultured organisms. However, working with metagenomes in non-native systems holds both promise and pitfalls. The benefits of using *E. coli* as a host organism are well-known: *E. coli* has an unrivaled fast growth on inexpensive media and the genetics are very well-known, making transformations with exogenous DNA simple and straightforward ([@B32]). In contrast, expression of a metagenomic fragment in a surrogate host may also entail cross-talks, inhibitions and unspecific reactions. Recombinant gene expression in *E. coli* and other surrogate hosts might be troublesome due to, e.g., unrecognized intrinsic promotors and associated factors, a diverging codon usage or problems with correct protein folding ([@B27]).

One major advantage of working with a metagenomic fragment in fosmid clones (besides gaining access to the world of the unculturables) is its relatively small size (in this case: 13 kb metagenomic fragment). The small size infers clear gene arrangements and a limited number of possible gene and/or protein interactions relative to the (hardly tangible) complexity in a native system. The same work in a cultured representative is considerably more difficult and time consuming, because genes with yet unknown functions, which are not necessarily located in the vicinity of the gene cluster under investigation, may well participate in/contribute to the gene regulation and activation of the enzyme (indirectly), as has recently been shown for *orf06* ([@B6]). Although the metagenomic approach with a defined number of genes can simplify first insights into regulatory mechanisms, it can also hinder the understanding of the mechanisms given that some vital genes/respective products cannot be expressed/synthesized as they are located on parts of the genome not present on the captured fraction of the metagenome.

To overcome such limitations the use of a host with the genomic inventory to operate the CBB cycle may be a viable option. In our case a cultured *Thiomicrospira* strain could be used and the genes under investigation deleted. However, deleting gene clusters in *T. crunogena* which are comparable to our 13 kb metagenomic fragment and expressing the latter heterologously in the *Thiomicrospira* host or alternatively constructing double mutants as we did in our metagenomic fragment (i.e., nine deletions in Δ*cbbL* and eight deletions in Δ*cbbM*) to investigate regulatory mechanisms is hardly feasible, given that *Thiomicrospira*'s genetic accessibility is not understood and thus any transformation with exogenous DNA becomes challenging. An alternative host that operates the CBB cycle and where mutations have been successfully constructed is *R. capsulatus* (*Alphaproteobacteria*) ([@B24]; [@B41]; [@B10]; [@B39]). However, this potential host encodes different types of RubisCOs and has other RubisCO gene cluster arrangements and likely different gene regulation mechanisms than the organism encoding our metagenomic fragment.

For future work one may consider combining studies in a genetically accessible surrogate host such as *E. coli*, naturally incapable of operating the CBB cycle, with subsequent investigations in a closely related cultured representative. Thus, the first insights of complex RubisCO regulatory mechanisms obtained through studies dealing with RubisCO gene expression in a non-native system could be used in further studies where, e.g., the role of external factors could be studied in a native system.

Conclusion
==========

The intense interactions between the different proteins suggest the complex, but fine-tuned nature of the RubisCO regulatory machinery. This fine-tuned regulatory machinery reflects the highly dynamic nature of hydrothermal vent environments from which this metagenomic fragment was extracted. Albeit the CBB cycle has a much higher energy requirement than other autotrophic CO~2~ fixation pathways ([@B4]), it can operate when O~2~ is present, while many enzymes of other CO~2~ fixation pathways are highly O~2~ sensitive ([@B3]). Given that RubisCO form I and form II have different capabilities to discriminate between CO~2~ and O~2~ ([@B3]) and both CO~2~ and O~2~ concentrations can be highly variable in hydrothermal vent habitats ([@B26] and references therein), the ability to rapidly react to environmental CO~2~ and O~2~ changes may pose a benefit for local organisms with both forms of RubisCO. A quick response to increasing O~2~ levels may be the key to successfully colonizing dynamic hydrothermal environments. Having understood some of the possible interactions between the proteins encoded by our metagenomic fragment, this knowledge could now be transferred to a closely related cultured representative. Distinct experiments under different environmental conditions such as high/low CO~2~ or O~2~ concentrations could be performed and changes in the transcriptome investigated.
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